7 December 2011 |
ENCePP Code of Conduct - Revision 2 The review also resulted in a revision of the Implementation Guidance for the Sharing of ENCePP Study Data (Annex 4 to the Code) providing further clarification on the Code’s requirement to provide access to data and the introduction of a form to declare interests (Annex 5). For more information see: - Summary of the main amendments introduced with the 2nd revision |
25 November 2011 |
ENCePP interpretation of the definition of non-interventional trialsOn 22 November 2011 the ENCePP Steering Group adopted the ENCePP position paper on the interpretation of the definition of non-interventional trials under the current legislative framework (“Clinical Trials Directive” 2001/20/EC). The aim of this position paper is to promote a common interpretation and understanding of the definition of ‘non-interventional trial’ in the context of the current legislative framework and based on widely accepted methodological definitions and clinical practice. This, in turn, is to further facilitate post-authorisation medicines research, thereby protecting and promoting public health. For more information see: - ENCePP interpretation of the defintion of non-interventional trials |
17 November 2011 |
ENCePP Linking Policy & Third Party Announcements in ENCePP Partners ForumThe ENCePP Steering Group recently adopted the 'ENCePP Linking Policy' providing guidance relating to links to third party websites and the announcement of third party activities on the ENCePP website. In parallel, a process has been put in place to deal with requests from third parties to post announcements in the ENCePP Partners Forum. For more information see: |
9 November 2011 |
ENCePP Plenary Meeting - 23 November 2011 The next ENCePP Plenary meeting will take place on Wednesday, 23 November 2011, 9.30-16.30 at the European Medicines Agency in London. ENCePP partners wishing to nominate a representative who will attend this event are invited to do so via the electronic pre-registration form. For further information see: |
28 September 2011 | ENCePP Information DayThe 2nd joint DIA/EMA ENCePP Information Day will be taking place on Monday, 7 November 2011 at the European Medicines Agency in London. This information day is aimed at pharmaceutical industry staff, in particular those responsible for risk management plans and post-authorisation studies (e.g. pharmacovigilance, pharmacoepidemiology and regulatory affairs) and academics, regulators, editors of medical journals, funding bodies and other professionals specialising in the field of observational research. For more information see: - ENCePP Information Day Programme To register for this event, please visit the DIA Website |
22 August 2011 |
ENCePP Checklist for Study ProtocolsOn 19 August 2011 the ENCePP Steering Group adopted the first revision of the Checklist of Methodological Standards for ENCePP Study Protocols. The major outcome of the revision has been to make the Checklist a 'stand-alone' document in line with the ENCePP Guide on Methodological Standards. This also reflects more general use of the Checklist outside the context of an application for ENCePP study status. The name of the Checklist has, therefore, been amended to "ENCePP Checklist for Study Protocols" (Revision 1). The revision does not, however, interfere with the Checklist being a requirement for ENCePP studies and for obtaining an ENCePP seal. For more information see: |
19 August 2011 |
ENCePP Workshop with Medical Journal EditorsOn 29 June 2011 a workshop with medical journal editors took place with the aim of introducing ENCePP and its key principles to journal editors and to obtain their feedback on the initiative. A record of the meeting is available here. |
28 July 2011 |
7th ENCePP Plenary MeetingThe seventh plenary meeting of ENCePP which took place on 30 June 2011 has heard that the network has grown considerably over the past few months, with over 100 resources from 17 different European countries now registered. With a record attendance from ENCePP partners, the meeting featured sessions on the possible interaction between ENCePP and health-technology-assessment bodies and the definition of non-interventional trials. Representatives from the United States Food and Drug Administration and Health Canada also attended, providing updates on their national initiatives on the safety monitoring of medicines after authorisation. Meeting report: |
01 June 2011 |
ENCePP Plenary Meeting – 30 June 2011The next ENCePP Plenary meeting will take place on Thursday, 30 June 2011, 9.30-16.30 at the European Medicines Agency in London. ENCePP partners wishing to nominate a representative who will attend this event are invited to do so via the electronic pre-registration form. For further information see: - Mandate and Rules of Procedure of the ENCePP Plenary - Draft Agenda (Update 22 June 2011) |
01 June 2011 |
ENCePP Reponse to the Revision of the CT DirectiveENCePP has submitted a response to the European Commission’s public consultation on the concept paper on the revision of the ‘Clinical Trials Directive’ 2001/20/EC. The key message from ENCePP is in relation to an amended definition of a non-interventional trial and a link to the ENCePP contribution is provided below. For more information see: |
23 May 2011 |
ENCePP Q & AA new Q&A section has been added to this website which provides answers to the most frequently asked questions about ENCePP and its key principles. Please see: ENCePP Q & A |
17 May 2011 |
Guide on Methodological Standards in PharmacoepidemiologyOn 3 May 2011 the ENCePP Steering Group adopted the Guide on Methodological Standards in Pharmacoepidemiology, an important tool that reviews and gives direct electronic access to methodological guidance for research in pharmacoepidemiology and pharmacovigilance. The guide provides a framework for thinking and learning on study design and methods through the presentation of internationally agreed recommendations and key points from important English-language guidelines, published articles and textbooks. The intention is to go further than compile an inventory of existing guidelines and to offer the researcher a single overview document and web resource with a brief introduction or overview of the relevant recommendations. Gaps in guidance in areas important to collaborative pharmacoepidemiology research have been addressed with what ENCePP considers as good practice. The guide focuses on scientific rather than regulatory guidance. For more information see: |
06 April 2011 |
ENCePP Activities 2010The ENCePP Secretariat has published an executive summary of ENCePP Activities 2010 which is available here. |
29 March 2011 |
Public Access to a Number of EudraCT Data FieldsSince 2004 it is mandatory for sponsors of clinical trials to register their application with EudraCT, the EU clinical trials database. As of 22 March 2011, the European Medicines Agency released to the public an extract from EudraCT that allows the search for information on clinical trials in European Union (EU) member states and the European Economic Area (EEA) and clinical trials which are conducted outside the EU/EEA if they form part of a paediatric investigation plan (PIP). Users can find information on the design of each clinical trial, the sponsor, the investigational medicinal products, the therapeutic areas involved and the status (authorised, ongoing, complete) of the clinical trial, but the website does not provide information on the results of clinical trials. Historical data (information entered into the EudraCT database between 1 May 2004 and the release of version 8.0 of the EudraCT database on 10th March 2011) will be gradually published online from 22 March 2011. For more information see: |
02 February 2011 |
ENCePP Response to Public Consultation on the Commission's comprehensive approach on personal data protection in the European Union ENCePP has submitted a statement to the European Commission in response to the public consultation on the Commission's communication on a comprehensive approach on personal data protection in the European Union. For more information see: - Commission communication on data protection COM(2010)609 of 4/11/2010 |